Showing results (921-930 of 1,376) with videos related to

Sort By:
Pageof 138
Drug Development Research|March 13, 2025
Strategies for the Discovery and Design of Tissue Plasminogen Activators: Insights Into Bioengineering ObjectivesAmirhossein Akbarpour Arsanjani, Davood Rabiei Faradonbeh, Ziba Veisi Malekshahi, et al.
Drug Development Research|October 28, 2024
Molecular docking, DFT and antiproliferative properties of 4-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine as potent anticancer agent with CDK2 and PIM1 inhibition potencyFaizah A Binjubair, Basma S Almansour, Noha I Ziedan, et al.
Drug Development Research|October 23, 2024
Role of BIX01294 in the intracranial inhibition of H3K9 methylation lessens neuronal loss in vascular dementia modelFardin Sehati, Saereh Hosseindoost, Mina Ranjbaran, et al.
Drug Development Research|October 15, 2024
RecQ protein-like 4 drives cisplatin chemosensitivity of cervical cancer cells by modulating annexin A2Ruixue Wang, Yunyan Zhang
Drug Development Research|October 14, 2024
EGCG enhances antitumor effect of apatinib in nonsmall cell lung cancer by targeting VEGF signaling to inhibit glycolysisYue Zhou, Liqing Qin, Chengpeng Li, et al.
Drug Development Research|October 11, 2024
Trifolirhizin targets PTK6 to induce autophagy and exerts antitumor effects in nasopharyngeal carcinomaYong Wang, Yang Fang
Drug Development Research|August 6, 2024
RETRACTION: "Dose-dependent Chemopreventive Effects of Citronellol in DMBA-Induced Breast Cancer Among Rats"
Drug Development Research|August 6, 2024
Design, synthesis, molecular modeling, in vitro evaluation of novel piperidine-containing hydrazone derivatives as cholinesterase inhibitorsFatih Tok, Nimet Baltaş, Burçin İrem Abas, et al.
Drug Development Research|August 6, 2024
Targeted degradation of KRAS protein in non-small cell lung cancer: Therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profilesXiaowen Wang, Linyu Su, Chong Niu, et al.
Drug Development Research|July 14, 2024
Study on the role of MYCN in retinoblastoma by inhibiting p53 and activating wnt/βcatenin/Fra-1 signaling pathway by reducing DKK3Xinke Chen, Lijuan Ouyang, Ning Ke, et al.
Pageof 138